Does device make any difference? A real-world retrospective study of insulin treatment among elderly patients with type 2 diabetes

Journal of Diabetes Science and Technology

Volumn 8, Issue 1, 2014, Pages 150-158

  Miao, Raymond ^a   Wei, Wenhui ^a   Lin, Jay ^b   Xie, Lin ^c   Baser, Onur ^c,d  

^a SANOFI   (France)

^b Novosys Health   (United States)

^c STATINMED RESEARCH   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Elderly; Insulin glargine; Pen; Type 2 diabetes

Indexed keywords

INSULIN GLARGINE; SOLOSTAR; UNCLASSIFIED DRUG;

AGED; ARTICLE; CONTROLLED STUDY; DEVICE COMPARISON; DRUG DOSAGE FORM COMPARISON; FEMALE; FOLLOW UP; GERIATRIC PATIENT; HEALTH CARE COST; HUMAN; INSULIN HYPOGLYCEMIA; INSULIN INJECTION PEN; INSULIN TREATMENT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; SEALED CONTAINER; SYRINGE; TREATMENT DURATION; TREATMENT OUTCOME; VIAL;

EID: 84900549465     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296813516956     Document Type: Article

References (43)

1. International Diabetes Foundation. Risk factors, 2011. www.idf.org/about-diabetes/risk-factors. Accessed January 6, 2012.
2. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf. Accessed January 6, 2012.
3. Resnick HE, Heineman J, Stone R, Shorr RI. Diabetes in U.S. nursing homes, 2004. Diabetes Care. 2008;31(2):287-288.
4. Russell LB, Valiyeva E, Roman SH, Pogach LM, Suh DC, Safford MM. Hospitalizations, nursing home admissions, and deaths attributable to diabetes. Diabetes Care. 2005;28(7):1611-1617.
5. American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care. 2012;35(suppl 1):S11-S63.
6. Suh D-C, Kim C-M, Choi I-S, Plauschinat CA. Comorbid conditions and glycemic control in elderly patients with type 2 diabetes mellitus, 1988 to 1994 to 1999 to 2004. J Am Geriatr Soc. 2008;56(3):484-492.
7. Travis SS, Buchanan RJ, Wang S, Kim MS. Analyses of nursing home residents with diabetes at admission. J Am Med Dir Assoc. 2004;5:320-327.
8. Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. Diabetes Care. 2012;35:2650-2664.
9. Fravel MA, McDanel DL, Ross MB, Moores KG, Starry MJ. Special considerations for treatment of type 2 diabetes mellitus in the elderly. Am J Health Syst Pharm. 2011;68(6):500-559.
10. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008;31(1):173-175.
11. Coscelli C, Lostia S, Lunetta M, Nosari I, Coronel GA. Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old. Diabetes Res Clin Pract. 1995;28(3):173-177.
12. Kadiri A, Chraibi A, Marouan F, et al. Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents. Diabetes Res Clin Pract. 1998;41(1):15-23.
13. Korytkowski M, Bell D, Jacobsen C, Suwannasari R, FlexPen Study Team. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25(11):2836-2848.
14. Keith K, Nicholson D, Rogers D. Accuracy and precision of low-dose insulin administration using syringes, pen injectors, and a pump. Clin Pediatr (Phila). 2004;43(1):69-74.
15. Korytkowski M, Niskanen L, Asakura T. FlexPen: addressing issues of confidence and convenience in insulin delivery. Clin Ther. 2005;27(suppl B):S89-S100.
16. Brunton S. Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens. Diabetes Technol Ther. 2008;10(4):247-256.
17. Carter J, Beilin J, Morton A, De Luise M. Usability, participant acceptance, and safety of a prefilled insulin injection device in a 3-month observational survey in everyday clinical practice in Australia. J Diabetes Sci Technol. 2009;3(6):1425-1438.
18. Hancu N, Czupryniak L, Genestin E, Sourij H. A Pan-European and Canadian prospective survey to evaluate patient satisfaction with the SoloSTAR insulin injection device in type 1 and type 2 diabetes. J Diabetes Sci Technol. 2011;5(5):1224-1234.
19. Goldstein HH. Pen devices to improve patient adherence with insulin therapy in type 2 diabetes. Postgrad Med. 2008;120(3):172-179.
20. Marcus A. Diabetes care - insulin delivery in a changing world. Medscape J Med. 2008;10(5):120.
21. Shaghouly AA, Shah BR. The prescription of insulin pen devices versus syringes for older people with diabetes. Diabetes Technol Ther. 2009;11(7):439-442.
22. Davis SN, Wei W, Garg S. Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting. Endocr Pract. 2011;17(6):845-852. doi:10.4158/EP10401.OR
23. Xie L, Wei W, Pan C, Du J, Baser O. A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens. Adv Ther. 2011;28(11):1000-1011. doi:10.1007/s12325-011-0074-5
24. Baser O, Wei W, Baser E, Xie L. Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID. J Med Econ. 2011;14(6):673-680. doi:10.3111/13696998.2011.605818
25. Levin P, Wei W, Wang L, Pan C, Douglas D, Baser O. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes. Curr Med Res Opin. 2012;28(3):439-446. doi:10.1185/03007995.2012. 654850
26. Xie L, Zhou S, Wei W, Gill J, Pan C, Baser O. Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2013;15(3):230-236.
27. Baser O, Bouchard J, DeLuzio T, Henk H, Aagren M. Assessment of adherence costs of insulin device (FlexPen®) versus conventional vial/syringe. Adv Ther. 2010;27(2):94-104.
28. Zhao Y, Campbell CR, Fonseca V, Shi L. Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes. Diabetes Care. 2012;35(5):1126-1132.
29. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
30. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301(15):1565-1572.
31. Asche CV, Luo W, Aagren M. Differences in rates of hypoglycaemia and health care costs in patients treated with insulin aspart in pens versus vials. Curr Med Res Opin. 2013;29:1287-1296.
32. Molife C, Lee LJ, Shi L, Sawhney M, Lenox SM. Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe. Diabetes Technol Ther. 2009;11(8):529-538.
33. Schwartz S, Khutoryansky N, Braceras R. Comparison of resource utilisation, preference and handling of a pre-filled pen and vial-syringe in patients with type 2 diabetes mellitus. J Clin Res. 2007;10:1-10.
34. Lin J, Wei W, Vlajnic A, et al. Real-world practice pattern and outcomes of patients with type 2 diabetes (T2DM) initiating injectable therapy via insulin glargine disposable pen (GLA-P) or liraglutide (LIRA). Diabetes. 2012;61(suppl 1):A286.
35. Xie L, Wei W, Pan C, Baser O. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies. J Med Econ. 2013;16(9):1137-1145.
36. Tanwani LK. Insulin therapy in the elderly patient with diabetes. Am J Geriatr Pharmacother. 2011;9(1):24-36.
37. Cobden D, Lee WC, Balu S, Joshi AV, Pashos CL. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy. 2007;27(7):948-962.
38. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 2006;28(10):1712-1725.
39. Lee LJ, Li Q, Reynolds MW, Pawaskar MD, Corrigan SM. Comparison of utilization, cost, adherence, and hypoglycemia in patients with type 2 diabetes initiating rapid-acting insulin analog with prefilled pen versus vial/syringe. J Med Econ. 2011;14(1):75-86.
40. Asche CV, Shane-McWhorter L, Raparla S. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence. Diabetes Technol Ther. 2010;12(suppl 1):S101-S108.
41. Niskanen L. A clinical and health economic review of a pre-filled insulin pen. Curr Med Res Opin. 2010;26(10):2431-2439.
42. Durso SC. Using clinical guidelines designed for older adults with diabetes mellitus and complex health status. JAMA. 2006;295(16):1935-1940.
43. Buysman E, Conner C, Aagren M, Bouchard J, Liu F. Adherence and persistence to a regimen of basal insulin in a pre-filled pen compared to vial/syringe in insulin-naïve patients with type 2 diabetes. Curr Med Res Opin. 2011;27(9):1709-1717.